Acadia Healthcare (NASDAQ:ACHC) Director Reeve B. Waud sold 7,698 shares of the business’s stock in a transaction on Thursday, March 15th. The shares were sold at an average price of $42.03, for a total value of $323,546.94. Following the completion of the sale, the director now owns 10,088 shares in the company, valued at approximately $423,998.64. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website.
Reeve B. Waud also recently made the following trade(s):
- On Friday, December 15th, Reeve B. Waud sold 100,000 shares of Acadia Healthcare stock. The shares were sold at an average price of $31.80, for a total value of $3,180,000.00.
Shares of NASDAQ:ACHC traded down $1.25 on Friday, hitting $39.46. 435,505 shares of the company’s stock were exchanged, compared to its average volume of 865,332. The stock has a market cap of $3,483.25, a P/E ratio of 17.16, a P/E/G ratio of 1.29 and a beta of 0.63. Acadia Healthcare has a 1-year low of $26.92 and a 1-year high of $54.34. The company has a debt-to-equity ratio of 1.25, a quick ratio of 1.25 and a current ratio of 1.25.
Acadia Healthcare (NASDAQ:ACHC) last announced its earnings results on Wednesday, February 21st. The company reported $0.61 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.54 by $0.07. The firm had revenue of $724.50 million during the quarter, compared to analysts’ expectations of $713.20 million. Acadia Healthcare had a return on equity of 8.16% and a net margin of 6.92%. The business’s revenue was up 3.1% on a year-over-year basis. During the same period in the prior year, the firm earned $0.59 EPS. equities research analysts predict that Acadia Healthcare will post 2.45 EPS for the current year.
ACHC has been the subject of several analyst reports. Wells Fargo initiated coverage on Acadia Healthcare in a research note on Tuesday, January 30th. They set an “outperform” rating and a $41.00 target price for the company. BMO Capital Markets reissued an “outperform” rating and set a $45.00 target price (up from $40.00) on shares of Acadia Healthcare in a research note on Friday, February 23rd. Robert W. Baird reissued a “hold” rating and set a $37.00 target price on shares of Acadia Healthcare in a research note on Friday, December 15th. Credit Suisse Group reissued a “neutral” rating and set a $40.00 target price (up from $35.00) on shares of Acadia Healthcare in a research note on Thursday, February 22nd. Finally, BidaskClub raised Acadia Healthcare from a “sell” rating to a “hold” rating in a research note on Friday, February 2nd. One analyst has rated the stock with a sell rating, six have assigned a hold rating, eleven have assigned a buy rating and one has given a strong buy rating to the company’s stock. Acadia Healthcare has an average rating of “Buy” and a consensus target price of $44.50.
Several hedge funds and other institutional investors have recently made changes to their positions in the stock. Aperio Group LLC boosted its position in shares of Acadia Healthcare by 4.8% in the 3rd quarter. Aperio Group LLC now owns 30,187 shares of the company’s stock valued at $1,442,000 after purchasing an additional 1,370 shares during the period. Tyers Asset Management LLC boosted its position in shares of Acadia Healthcare by 31.8% in the 4th quarter. Tyers Asset Management LLC now owns 5,904 shares of the company’s stock valued at $193,000 after purchasing an additional 1,424 shares during the period. American International Group Inc. boosted its position in shares of Acadia Healthcare by 1.1% in the 4th quarter. American International Group Inc. now owns 168,938 shares of the company’s stock valued at $5,512,000 after purchasing an additional 1,836 shares during the period. Eagle Boston Investment Management Inc. boosted its position in shares of Acadia Healthcare by 1.5% in the 3rd quarter. Eagle Boston Investment Management Inc. now owns 126,677 shares of the company’s stock valued at $6,031,000 after purchasing an additional 1,852 shares during the period. Finally, Boston Private Wealth LLC boosted its position in shares of Acadia Healthcare by 2.6% in the 3rd quarter. Boston Private Wealth LLC now owns 88,019 shares of the company’s stock valued at $4,204,000 after purchasing an additional 2,260 shares during the period.
COPYRIGHT VIOLATION WARNING: This news story was first posted by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are accessing this news story on another publication, it was illegally copied and republished in violation of United States & international copyright & trademark legislation. The legal version of this news story can be viewed at https://www.dispatchtribunal.com/2018/04/08/reeve-b-waud-sells-7698-shares-of-acadia-healthcare-company-inc-achc-stock.html.
Acadia Healthcare Company Profile
Acadia Healthcare Company, Inc is a provider of behavioral healthcare services, with operations in the United States and the United Kingdom. The Company focuses on acquiring and developing behavioral healthcare facilities. The Company operates through two segments: U.S. Facilities and U.K. Facilities.
Receive News & Ratings for Acadia Healthcare Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acadia Healthcare and related companies with MarketBeat.com's FREE daily email newsletter.